World Wires · story 5197 · unverified · 1 source(s)

Unicycive Resubmits NDA for Oxylanthanum Carbonate

Unicycive Therapeutics resubmitted its New Drug Application to the FDA for oxylanthanum carbonate as a treatment for kidney disease patients.

Open in the desk

Coverage

• Unicycive Resubmits NDA for Oxylanthanum Carbonate GlobeNewswire: public companies · tier D · clear net · 2026-09-29 11:05 UTC

What this site indexes